Research Article

Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients

Figure 4

The Kaplan-Meier curves for clinical or radiographic progression-free survival outcomes for all Enza-treated CRPC patients with different expression patterns of CXCR7 (P: CXCR7- vs. CXCR7+; P1: CXCR7/1+ vs. CXCR7/2+; P2: CXCR7/2+ vs. CXCR7/3+; P3: CXCR7/1+ vs. CXCR7/3+).
(a)
(b)